anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a process by which smoothness, body and a permanent wave pattern can be imparted to multi-textured hair of all types, from hair having an excessively thightly curled appearance, such as Negroid hair, to hair having a straight appearance, such as Caucasian hair, with substantially less damage to the hair. The process of the present invention uniquely combines the use of two hair structure altering chemicals -- an alkaline hydroxide (such as sodium hydroxide) and a thioglycolate reducing agent (preferably ammonium thioglycolate) -- to harmoniously bring about a desired wave pattern in the hair. Using the Wave Balance Scale (a hair reference scale) of the present invention, a sodium hydroxide formulation is chosen based on the type and natural curl level of the hair. The sodium hydroxide formulation is applied to the hair for a time sufficient to relax the natural curl in the hair by breaking some of the sulfide bonds in the hair. Then, after rinsing but prior to any neutralization, the ammonium thioglycolate formulation is applied to the hair and the hair is placed on curling rods for a time sufficient to rearrange the wave pattern of the relaxed hair. The hair is then rinsed and neutralized, while still rodded, for a time sufficient to lock in the new wave pattern by reforming the sulfide bond linkages. After neutralization, the hair can be shampooed, conditioned and styled either curly or straight as desired by the patron.
BACKGROUND: In Japan, the public insurance policy was revised in 2020 to cover hereditary breast and ovarian cancer (HBOC), including genetic testing and surveillance, for patients with breast cancer (BC). Consequently, the demand for risk-reducing salpingo-oophorectomy (RRSO) has increased. This study aimed to clarify the changes in the demand and timing of genetic testing and RRSO associated with public insurance coverage for HBOC in Japan.
METHODS: This retrospective analysis included 350 women with germline BRCA (gBRCA) pathogenic variants (PVs) who had visited gynaecologists; they received gBRCA genetic testing at 45.1±10.6 (20-74) years. The use of medical testing and preventive treatment was compared between the preinsurance and postinsurance groups using Mann-Whitney U and Fisher's exact tests.
RESULTS: The findings indicate that RRSO rates doubled from 31.4% to 62.6% among patients with gBRCA-PV. The implementation rate was 32.4% among unaffected carriers and 70.3% among BC-affected patients. Younger patients received genetic testing with significantly shorter intervals between BC diagnosis and genetic testing and between genetic testing and RRSO.
CONCLUSION: Overall, the insurance coverage for HBOC patients with BC has increased the frequency of RRSO in Japan. However, a comparison between the number of probands and family members indicated that the diagnosis among family members is inadequate. The inequality in the use of genetic services by socioeconomic groups is an issue of further concern.
Polymorphonuclear neutrophil (PMN) infiltration at inflammatory site plays a critical role in inflammation. PMN reverse migration (rM) describes the phenomenon that PMNs migrate away from inflammatory site back into the vasculature, and its role within inflammatory scenarios remains to be fully determined. This study aimed to investigate the mechanism underlying PMN rM and its role in inflammation. First, we demonstrated PMN rM in a mouse model of lipopolysaccharide-induced acute lung inflammation. By single-cell RNA sequencing, we demonstrated that reverse migrated (rM-ed) PMNs in blood expressed a high level of immune-responsive gene 1 (Irg1), the encoding gene of cis-aconitate decarboxylase (ACOD1). Using a mouse air pouch model, which enabled us to directly track rM-ed PMNs in vivo, we detected higher expression of ACOD1 in the rM-ed PMNs in circulation. Furthermore, mice with Irg1 knockout exhibited decreased PMN rM and higher levels of inflammatory cytokine in inflammatory site. Mechanistically, we found that itaconate, the product of ACOD1 catalyzation, decreased PMN ICAM-1 expression at the inflammation site. Furthermore, inflammatory site showed a high level of shed Cd11a, the ligand of ICAM-1. Neutralization of either ICAM-1 or Cd11a led to increased PMN rM. These findings suggest that the binding of ICAM-1 and shed Cd11a serves as a retaining force to hold PMNs in the site of inflammation, and ACOD1-decreased PMN surface expression of ICAM-1 weakens the retaining force, promoting PMNs to leave the inflammatory site. These results indicate a regulatory role of IRG1 in PMN rM and subsequent contributions to inflammation resolution.
Irreversible alveolar airspace enlargement is the main characteristic of pulmonary emphysema, which has been extensively studied using animal models. While the alterations in lung mechanics associated with these morphological changes have been documented in the literature, the study of the mechanical behavior of parenchymal tissue from emphysematous lungs has been poorly investigated. In this work, we characterize the mechanical and morphological properties of lung tissue in elastase-induced emphysema rat models under varying severity conditions. We analyze the non-linear tissue behavior using suitable hyperelastic constitutive models that enable to compare different non-linear responses in terms of hyperelastic material parameters. We further analyze the effect of the elastase dose on alveolar morphology and tissue material parameters and study their connection with respiratory-system mechanical parameters. Our results show that while the lung mechanical function is not significantly influenced by the elastase treatment, the tissue mechanical behavior and alveolar morphology are markedly affected by it. We further show a strong association between alveolar enlargement and tissue softening, not evidenced by respiratory-system compliance. Our findings highlight the importance of understanding tissue mechanics in emphysematous lungs, as changes in tissue properties could detect the early stages of emphysema remodeling. STATEMENT OF SIGNIFICANCE: Gas exchange is vital for life and strongly relies on the mechanical function of the lungs. Pulmonary emphysema is a prevalent respiratory disease where alveolar walls are damaged, causing alveolar enlargement that induces harmful changes in the mechanical response of the lungs. In this work, we study how the mechanical properties of lung tissue change during emphysema. Our results from animal models show that tissue properties are more sensitive to alveolar enlargement due to emphysema than other mechanical properties that describe the function of the whole respiratory system.
Children will be exposed to recasts at a rate of 1/minute. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 recasts). 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed Speech Language Pathologist (SLP).
FIELD: chemistry. ^ SUBSTANCE: invention relates to agriculture. The herbicide agent contains an active substance or chemical modification thereof and a surfactant. The active substance is aryloxycarboxylic acid, 3,6-dichloropyridine-2-carboxylic acid or 2-methoxy-3,6-dichlorobenzoic acid. The chemical modification of the active substance is in form of esters of these acids having normal and isomeric structure. The surfactant is a trialkylamine salt containing one alkyl radical with not less than 8 carbon atoms. The salt is synthesised from the corresponding tertiary alkylamine and the said acid. ^ EFFECT: invention increases concentration of active substance in the herbicidal preparation. ^ 3 cl, 3 ex, 2 tbl
Children aged 5-18 years (boys, girls) with type 1, type 2 and monogenic diabetes mellitus who are treated at the Endocrinology Department and Outpatient Clinic of Heim Pál National Pediatric Institute (HOGYI, Budapest, Hungary) will be enrolled. Definition of diabetes is based on the American Diabetes Association (ADA) criteria. All patients who meet the inclusion criteria will be informed of the possibility of taking part in the INTACT Trial.
Participants take mirabegron + alpha lipoic acid daily for 4 weeks. There is testing pre- and post-treatment. Will evaluate the effects of MG+ALA on metabolic heath.
Garlic (Allium sativum) is recognized as functional food, rich in bioactive compounds that can combat diseases associated with oxidative stress. This study aims to investigate the protective potential of aqueous garlic extract against hemolysis and oxidation. Despite being caused by membrane fragility, hemolysis can lead to inflammation through the oxidation of its products, and in some cases, even exacerbate it in certain pathological contexts. Supplementation with antioxidant molecules can improves oxidative status, in this study, we selected garlic, an excellent functional food, and targeted its effects using aqueous extract and pure molecules. The aqueous garlic extract was prepared under safe conditions and subjected to toxicity on human neutrophils and red blood cells before experimentation. The results indicate that aqueous garlic extract significantly reduces hemolysis with a maximum protection of  98. 74 ± 1. 08 % at a concentration of 5μg/ml. Additionally, experiments were conducted with pure compounds found in garlic such as quercetin, gallic acid, and caffeic acid. The outcomes show that quercetin reduces hemolysis of RBC with a maximum protection of  88. 8 ± 2. 89 % at 20 µM followed by caffeic acid and gallic acid. The action mechanism of the extract was tested on human neutrophil cells, the extract significantly reduced luminol-amplified chemiluminescence of PMA-stimulated neutrophils up to 50 % at 10 µg/ml in addition to its ability to directly scavenge hydrogen peroxide. Our results suggest that aqueous garlic extract exerts promising anti-inflammatory activity in vitro. Through its dual protection against hemolysis and Ros production, garlic may indirectly prevent inflammation reducing the oxidation of hemolysis products. These abilities make garlic aqueous extract promising candidate for improving cardiovascular health, reducing oxidative stress and modulating immunity.
A computer includes a user activity monitor 60 which monitors usage of the computer by a user. On usage reaching predetermined thresholds, for instance in terms of either actual keystrokes or usage time (time adjusted for breaks), the user activity manager 60 outputs instructions to the user to cause the user to take a break. The instructions relate to exercises such as stretches (or eye exercises) to be done so as to prevent possible repetitive strain injury (RSI). The instructions may be skipped. Periodically the user is prompted to answer a questionnaire, regarding for example their seating position and their posture and feedback is given on their answers if they are not eg. seated correctly (a system administrator may be notified). Both the users' answers to the questionnaires and their responses to the activity manager are logged for future reference in order to provide evidence of a safe working environment.
In Kenya, up to 46% of women report childhood sexual assault. In an implementation research project, a team at Stanford University will be pairing with three Kenyan NGO's to research the effectiveness of an intervention to prevent sexual assault among adolescent girls in the informal settlements around Nairobi, Kenya. The study design will be a cluster-randomized controlled trial with two arms comparing the intervention to a standard of care group. The intervention consists of two side-by-side behavioral and skills-based interventions, one for girls and one for boys, taught in schools. The interventions include identifying and avoiding risky situations, verbal techniques to diffuse situations, as well as bystander intervention techniques for boys and self-defense techniques for girls. Settlements with schools participating in the project include Kibera, Dandora, Huruma, and Mukuru.

This grant is part of the larger "What Works to Prevent Violence: A global program to prevent violence against women and girls" initiative, which is a large international initiative aimed at the prevention of gender-based violence. The initiative includes 18 projects from around the globe, and is supported by the Medical Research Council of South Africa, the London School of Hygiene and Tropical Medicine, and the UK Department for International Development (DFID). The primary contact people at Stanford University for this project are Clea Sarnquist, DrPH, MPH (cleas@stanford.edu) and Michael Baiocchi, PhD (baiocchi@stanford.edu).
PROBLEM TO BE SOLVED: To provide particle or fine particle which is so modified to provide enhanced anti-inflammatory effect and/or antibiotic effect.SOLUTION: The invention relates to implant which has anti-inflammatory or antibiotic effect or both of them and being expected to be injected into a human body or animal body. The implant comprises at least one porous fine particle or particle. The at least one porous fine particle or particle comprises titanium, one or plural kinds of titanium oxide, or titanium alloy. The implant has a layer of the titanium oxide on its surface. The average length from one side to the opposite side via the geometrical center is of at most 5 mm. The surface area of average ratio is at least 0.15 m/g according to the BET method. In addition, it is disclosed a method for therapy for a symptom comprising inflammation and/or infection in a human body or animal body with the implant of the invention. It is also described a method for production of the implant of the invention.
NEW MATERIAL:Compounds expressed by formula I (R<1> is 4-20C straight-chain or branched chain alkyl; R<2> is H or protecting group of OH; R<3> is H or protecting group of COOH) and salt thereof. EXAMPLE:(+ or -)-tert-Butyl syn-2-fluoro-3-hydroxymyristate. USE:An aldose reductase inhibitor useful as a remedy for diabetic complications (e.g., cataract). PREPARATION:A compound expressed by formula II and a compound expressed by formula III are subjected to aldose condensation reaction according to the Welch and Seper method to provide a compound expressed by formula IV, which is then reacted with an alkaline earth metal monoperphthalate by the Baeyer-Villiger reaction to afford a compound expressed by formula V in the compounds expressed formula I. Furthermore, the carboxyl-protecting group, as desired, is removed or the hydroxyl group at the 3-position is protected with a protecting group. The carboxyl-protecting groups, as desired, is removed to provide compounds expressed by formulas VI-VIII in the compounds expressed by formula I.
Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
INTRODUCTION: Obesity, characterized by excess adipose tissue, is a major public health problem worldwide. Brown adipose tissue (BAT) and beige adipose tissue participate in thermogenesis through uncoupling protein 1 (UCP1). Polyphenols including those from Calafate (a native polyphenol-rich Patagonian berry), are considered as potential anti-obesity compounds due to their pro-thermogenic characteristics. However, polyphenols are mainly metabolized by the gut microbiota (GM) that may influence their bioactivity and bioavailability. The aim of this study was to determine the impact of dietary administration with a Calafate polyphenol-rich extract on thermogenic activity of BAT and beige adipose tissue and GM composition.
METHODS: Eight-week-old C57BL6 mice (n = 30) were divided into 4 groups to receive for 24 weeks a control diet (C), a high-fat diet alone (HF), or high-fat diet supplemented with Calafate extract (HFC) or the same high-fat diet supplemented with Calafate extract but treated with antibiotics (HFCAB) from week 19-20. Administration with Calafate extract (50 mg/kg per day) was carried out for 3 weeks from week 21-23 in the HFC and HFCAB groups. After euthanasia, gene expression of thermogenic markers was analyzed in BAT and inguinal white adipose tissue (iWAT). Transmission electron microscopy was performed to assess mitochondrial morphology and cristae density in BAT. GM diversity and composition were characterized by deep sequencing with the MiSeq Illumina platform.
RESULTS: Calafate extract administration had no effect on weight gain in mice fed a high-fat diet. However, it prevented alterations in mitochondrial cristae induced by HFD and increased Dio2 expression in BAT and iWAT. The intervention also influenced the GM composition, preventing changes in specific bacterial taxa induced by the high-fat diet. However, the antibiotic treatment prevented in part these effects, suggesting the implications of GM.
CONCLUSION: These results suggest that the acute administration of a Calafate extract modulates the expression of thermogenic markers, prevents alterations in mitochondrial cristae and intestinal microbiota in preclinical models. The study highlights the complex interaction between polyphenols, thermogenesis, and the GM, providing valuable insights into their potential roles in the treatment of obesity-related metabolic diseases.
The invention provides a preparation method and application of a red sage root composite zinc-carbon dot wrapped by apoptosis bodies, belonging to the fusion development of biological medicine and materials. The particle size of the red sage root composite zinc carbon point is about 8-10nm, which meets the particle size requirement of nano material. The cells were induced by adding 0.2-0.8. Mu.M staurosporine to a commercially available normal hepatocyte culture dish, such that the cells exhibited a tendency to apoptosis. After the cell culture medium is changed, adding the red sage root compound zinc carbon point to induce for 8-14 hours, collecting apoptosis corpuscles, and obtaining the red sage root compound zinc carbon point with hepatic cell apoptosis corpuscle wrapping. The red sage root composite zinc carbon point with the small body package of the hepatic cell apoptosis has the capability of inducing the death of the hepatic cell cancer, thereby inhibiting the progression of the hepatic cell cancer, being capable of being used for biological pharmacy and having tumor cell targeting.
Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.  
  
  
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. (See PRECAUTIONS: General and DOSAGE AND ADMINISTRATION.)
The incidence of obesity is growing at an alarming pace and has reached epidemic proportions. Subjects who are more than 100 pounds over their ideal body weight are classified as being morbidly obese and are considered to carry a high risk for multiple chronic medical conditions that impact quality of life and shorten life span. As a result of obesity, these individuals are also at a higher risk for developing life-threatening blood clots. Such risk is further elevated with exposure of obese subjects to the stress of surgery. In fact, the most common cause of death after major surgery in morbidly obese subjects is the migration of blood clots to the lung and heart. With the current rise in popularity of weight loss surgery, it has become imperative that we identify a medication that is safe and effective in preventing the formation of blood clots. Fondaparinux has the potential for being an effective anti-clotting drug. It is superior to other similar drugs because it is completely utilized by the body, and has a more predictable action. The problem, however, is that the recommended doses for fondaparinux were obtained after studies on lean individuals. This is a fixed dose that is administered universally, regardless of the size of the subject. Presently, we have no information on what the recommended doses should be for morbidly obese subjects, who are in the most need for effective anti-clotting medication. This study will attempt to determine whether a fixed dose or a weight-related dose is appropriate for morbidly obese subjects, and also investigate the safety of administering weight-based dosing to these individuals.
The present invention involves an oligonucleotide probe useful to select recombinant unicellular clones producing a polynucleotide sequence containing the genetic code for the amino acid sequence of mumps virus hemagglutinin-neuraminidase. The use of probes such as these permits the selection from mumps virus gene libraries of unicellular clones bearing recombinant DNA vector comprising a first base sequence which codes for the amino acid sequence of pumps virus hemagglutinin-neuraminidase or a second base sequence complementary to said first base sequence. A recombinant DNA vector such as that would comprises a base sequence substantially as shown in Fig. 5. Additionally, a recombinant DNA vector comprising a first base sequence substantially as shown in Fig. 5 may alternatively comprise a second base sequence substantially complementary to said first base sequence. The recombinant DNA vector of the present invention may also be characterized as comprising a base sequence substantially complementary to a nucleic acid sequence coding for protein of mumps virus hemagglutinin-neuraminidase. A unicellular host such as, for example, Escherichia coli compatible with and containing such a recombinant vector is also part of the present invention. In an important aspect, the present invention involves a DNA molecule comprising a recombinant DNA vector having a DNA sequence which encodes mumps virus hemagglutinin-neuraminidase protein as defined by the amino acid sequence of Fig. 5. This molecule could also be characterized as being a substantially purified DNA molecule comprising a DNA sequence which encodes mumps virus hemagglutinin-neuraminidase protein as defined by the amino acid sequence of Fig. 5.